XNCR - XencorAbout Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
| Previous Close | $30.92 | Open | |
| Volume | Market Cap | 1.788B | |
| Yield | Last Dividend |
| Xencor Reports Second Quarter 2020 Finan... | 08/04/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor to Host Second Quarter 2020 Finan... | 07/28/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Atreca teams up with Xencor to develop T... | 07/08/20 |
| Atreca (NASDAQ:BCEL) is up 6% premarket after entering into a collaboration and license agreement with Xencor (NASDAQ:XNCR) to research, develop and c... | |
| Xencor Presents Data from Four Preclinic... | 06/22/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Applied BioMath, LLC Announces Two-year ... | 06/15/20 |
| CONCORD, Mass., June 15, 2020 /PRNewswire/ -- Applied BioMath (www.appliedbiomath.com), the industry-leader in applying systems pharmacology and mecha... | |
| Xencor to Present Data from Four Preclin... | 05/14/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Xencor to Present at the 2020 RBC Capita... | 05/13/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Xencor Reports First Quarter 2020 Financ... | 05/07/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor to Host First Quarter 2020 Financ... | 04/30/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| The Daily Biotech Pulse: FDA Nod For Bri... | 03/26/20 |
| Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs March 25.) ... | |
| Vir inks deal with Xencor for antibody-e... | 03/25/20 |
| Vir Biotechnology (NASDAQ:VIR) has in-licensed non-exclusive rights to Xencor's (NASDAQ:XNCR) Xtend Fc technology aimed at extending the half-lives of... | |
| Xencor and Vir Biotechnology Enter Licen... | 03/25/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor Reports Fourth Quarter and Full Y... | 02/24/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor to Host Fourth Quarter and Full Y... | 02/18/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Aimmune Licenses Exclusive Worldwide Rig... | 02/05/20 |
| BRISBANE, Calif.--(BUSINESS WIRE)--Aimmune Therapeutics, Inc. (Nasdaq: AIMT), a biopharmaceutical company developing treatments for potentially life-t... | |
| Gilead (GILD) Inks License Deal with Xen... | 01/09/20 |
| Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV... | |
| Xencor and Gilead Enter License Agreemen... | 01/08/20 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor Appoints Dagmar Rosa-Bjorkeson to... | 12/20/19 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies ... | |
| Xencor Appoints Allen Yang, M.D., Ph.D.,... | 12/18/19 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Xencor to Present Initial Data from the ... | 11/06/19 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Xencor Reports Third Quarter 2019 Financ... | 11/05/19 |
| MONROVIA, Calif.--(BUSINESS WIRE)--Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies... | |
| Xencor (XNCR) Reports Q2 Loss, Tops Reve... | 08/06/19 |
| Xencor (XNCR) delivered earnings and revenue surprises of 33.33% and 156.99%, respectively, for the quarter ended June 2019. Do the numbers hold clues... | |
| Along With FDA Clinical Hold Being Lifte... | 05/29/19 |
| No summary available. | |
| Xencor up 8% on Q1 beat | 05/10/19 |
| No summary available. | |
| Xencor up 5% on Q1 beat | 05/10/19 |
| No summary available. | |
| Xencor, Inc. (XNCR) CEO Bassil Dahiyat o... | 05/10/19 |
| Xencor, Inc. (NASDAQ:XNCR) Q1 2019 Earnings Conference Call May 09, 2019 4:30 PM ET Company Participants Charles Liles - Associate Director & Head of ... | |
| Xencor Inc (XNCR) Q1 2019 Earnings Call ... | 05/10/19 |
| XNCR earnings call for the period ending March 31, 2019. | |
| Xencor (XNCR) Beats Q1 Earnings and Reve... | 05/09/19 |
| Xencor (XNCR) delivered earnings and revenue surprises of 220.93% and 86.41%, respectively, for the quarter ended March 2019. Do the numbers hold clue... | |
| Xencor beats by $1.79, beats on revenue | 05/09/19 |
| No summary available. | |
| FDA lifts enrollment suspension on Xenco... | 04/30/19 |
| No summary available. | |
| Strong Buy rating | 12:00 AM |
| SVB Leerink maintains Outperform rating and lowers Price Target from $44.00 to $42.00 | |
| Date | 2020-08-04 (AMC) | Est. (EPS/Rev.) | ($0.50)/ 12.61M |
| Actual (EPS/Rev.) | $-0.61/ $13.09 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
